The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Interventions for valvular disease and heart failure

Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis

EuroIntervention 2021;17:e343-e352. DOI: 10.4244/EIJ-D-21-00191

1. Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany; 2. Division of Cardiac Surgery, University Heart Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 3. HELIOS Klinikum Erfurt, Department of General and Interventional Cardiology & Rhythmology, Erfurt, Germany; 4. Universitätsklinikum Charité, Campus Benjamin Franklin, Berlin, and German Centre for Cardiovascular Research (DZHK), Berlin, Germany; 5. Cardiology Department, Asklepios Klinik St. Georg, Hamburg, Germany; 6. Cardiology Department, St. Paul’s Hospital, Vancouver, BC, Canada; 7. Cardiology Department, Cardiocentro, Lugano, Switzerland; 8. Cardiology Department, Klinikum der Universität München, Munich, Germany; 9. Cardiology Department, Hôpital Bichat, Université Paris VI, Paris, France; 10. Cardiology Department, Toronto Heart Center, St. Michael's Hospital, Toronto, ON, Canada; 11. Cardiology Department, CardioVascular Center Frankfurt, Frankfurt am Main, Germany; 12. Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy; 13. Hospital Universitario Alvaro Cunqueiro, Vigo, Spain; 14. Cardiology Department, Montefiore Medical Center, New York, NY, USA; 15. University Heart & Vascular Center Hamburg, Hamburg, Germany; 16. Division of Cardiology, Yale University School of Medicine, New Haven, CT, USA; 17. Department of Cardiology, University Medical Center Mainz, Mainz, Germany; 18. Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain; 19. Cardiology Department, New York-Presbyterian/Columbia University Medical Center, New York, NY, USA; 20. Cardiology Department, Universitaetsklinikum Bonn, Bonn, Germany; 21. Cardiology Department, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 22. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA; 23. Cardiology Department, Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada; 24. Cardiology, Angiology and Intensive Care Medicine, Catholic Marienhospital, Hamburg, Germany; 25. MVZ Department Structural Heart Disease, Asklepios Klinik St. Georg, Hamburg, Germany; 26. Cardiac Surgery Department, Mount Sinai Hospital, New York, NY, USA; 27. University of Zurich, Zurich, Switzerland

Background: Tricuspid regurgitation (TR) has a poor prognosis and limited treatment options and is frequently accompanied by right ventricular (RV) dysfunction. Transcatheter tricuspid valve interventions (TTVI) to reduce TR have been shown to be safe and feasible with encouraging early results. Patient selection for TTVI remains challenging, with the role of right ventricular (RV) function being unknown.

Aims: The aims of this study were 1) to investigate survival in a TTVI-treated patient population and a conservatively treated TR population, and 2) to evaluate the outcome of TTVI as compared to conservative treatment stratified according to the degree of RV function.

Methods: We studied 684 patients from the multicentre TriValve cohort (TTVI cohort) and compared them to 914 conservatively treated patients from two tertiary care centres. Propensity matching identified 213 pairs of patients with severe TR. As we observed a non-linear relationship of RV function and TTVI outcome, we stratified patients according to tricuspid annular plane systolic excursion (TAPSE) to preserved (TAPSE >17 mm), mid-range (TAPSE 13-17 mm) and reduced (TAPSE <13 mm) RV function. The primary outcome was one-year all-cause mortality.

Results: TTVI was associated with a survival benefit in patients with severe TR when compared to matched controls (one-year mortality rate: 13.1% vs 25.8%; p=0.031). Of the three RV subgroups, only in patients with mid-range RV function was TTVI associated with an improved survival (p log-rank 0.004). In these patients, procedural success was associated with a reduced hazard ratio for all-cause mortality (HR 0.22; 95% CI: 0.09, 0.57).

Conclusions: TTVI is associated with reduced mortality compared to conservative therapy and might exert its highest treatment effect in patients with mid-range reduced RV function.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Fracture of the delivery catheter system during transcatheter aortic valve implantation